On April 2, 2019 Novocure (NASDAQ:NVCR) reported that it will report financial results for the first quarter 2019 on Thursday, May 2, 2019, before the U.S. financial markets open (Press release, NovoCure, APR 2, 2019, View Source [SID1234534922]). Novocure management will host a conference call and webcast to discuss its financial results for the three months ended March 31, 2019, at 8 a.m. EDT on Thursday, May 2, 2019.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Analysts and investors can participate in the conference call by dialing 855-442-6895 for domestic callers and 509-960-9037 for international callers, using the conference ID 8956998. The webcast and earnings slides presented during the webcast can be accessed live from the Investor Relations page of Novocure’s website, www.novocure.com/investor-relations, and will be available for replay for at least 14 days following the call.

On April 2, 2019 AVEO Oncology (NASDAQ: AVEO) reported that Michael Bailey, president and chief executive officer, will present at the H.C. Wainwright Global Life Sciences Conference in London on Tuesday, April 9, 2019 at 2:10 p.m. BST (Press release, AVEO, APR 2, 2019, View Source [SID1234534921]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the webcast will be archived for 30 days following the presentation date.

On April 2, 2019 AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, reported financial results for the third quarter of fiscal year 2019, which ended February 28, 2019 (Press release, AngioDynamics, APR 2, 2019, View Source [SID1234534920]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"While we had pockets of softness in our financial performance during the third quarter, our overall performance remains strong, and we are confident that we will achieve our full-year guidance. We saw strong growth contributions during the quarter from AngioVac and Solero, as well as from Fluid Management," commented Jim Clemmer, President and Chief Executive Officer of AngioDynamics, Inc. "Additionally, I am very excited that the FDA has approved the IDE for our NanoKnife DIRECT Clinical Study, which is the next step toward this incredible technology improving the standard of care for patients afflicted with Stage III pancreatic cancer. The IDE approval also represents a milestone for AngioDynamics as we transform into an evidence-based Company focused on therapies and outcomes facilitated by our unique technologies."

Third Quarter 2019 Financial Results

Net sales for the third quarter of fiscal 2019 were $86.3 million, an increase of 3.0%, compared to $83.9 million a year ago. Foreign currency translation did not have a significant impact on the Company’s sales in the quarter.

Oncology net sales were $13.9 million, an increase of 15.1% from $12.1 million a year ago, as strong sales of Solero, as well as the recent BioSentry and RadiaDyne acquisitions, more than offset weaker than anticipated NanoKnife capital sales during the quarter.
Vascular Interventions and Therapies net sales in the third quarter of fiscal 2019 were $50.1 million, an increase of 3.3%, compared to $48.5 million a year ago, as strong growth in AngioVac was partially offset by a decelerating decline in the Venous Insufficiency business.
Vascular Access net sales were $22.3 million, a decrease of 4.0% from $23.3 million a year ago, as lower sales of midlines, PICCs, and ports were somewhat offset by strong dialysis sales.
U.S. net sales in the third quarter of fiscal 2019 were $68.3 million, an increase of 3.9% from $65.8 million a year ago, and International net sales were $18.0 million, a decrease of 0.3% from $18.1 million a year ago.

Gross margin for the third quarter of fiscal 2019 declined 10 basis points to 54.1% from 54.2% a year ago. This reflects temporary headwinds related to FX and a one-time positive impact from plant closures recognized last year. The Company continues to see gains in gross margin related to operational and supply-chain improvements.

The Company recorded net income of $0.8 million, or $0.02 per share, in the third quarter of fiscal 2019. This compares to net income of approximately $14.0 million, or $0.37 per share, a year ago.

Excluding the items shown in the non-GAAP reconciliation table below, adjusted net income for the third quarter of fiscal 2019 was $7.4 million, or $0.19 per share, compared to adjusted net income of $8.7 million, or $0.23 per share, in the third quarter of fiscal 2018.

Adjusted EBITDAS in the third quarter of fiscal 2019, excluding the items shown in the reconciliation table below, was $14.9 million, compared to $16.8 million in the third quarter of fiscal 2018.

In the third quarter of fiscal 2019, the Company generated $8.3 million in operating cash flow and had capital expenditures of $0.9 million. As of February 28, 2019, the Company had $41.7 million in cash and cash equivalents and $133.8 million in debt, excluding the impact of deferred financing costs.

Nine Months Financial Results

For the nine months ended February 28, 2019:

Net sales were $263.2 million, an increase of 2.8%, compared to $256.0 million for the same period a year ago.
The Company’s net income was $2.5 million, or $0.06 per share, compared to net income of $14.2 million, or $0.38 per share, a year ago.
Gross margin improved 270 basis points to 53.3% from 50.6% a year ago.
Excluding the items shown in the non-GAAP reconciliation table below, adjusted net income was $22.0 million, or $0.57 per share, compared to adjusted net income of $19.9 million, or $0.53 per share, a year ago.
Adjusted EBITDAS, excluding the items shown in the reconciliation table below, was $43.9 million, compared to $41.5 million for the same period a year ago.
Fiscal Year 2019 Financial Guidance

The Company reiterates its previously announced financial guidance, continuing to expect fiscal year 2019 net sales in the range of $354 to $359 million and free cash flow in the range of $26 to $31 million. Additionally, the Company continues to expect adjusted earnings per share in the range of $0.82 to $0.86.

Conference Call

The Company’s management will host a conference call today at 8:00 a.m. ET to discuss its third quarter 2019 results.

To participate in the conference call, dial 1-877-407-0784 (domestic) or 1-201-689-8560 (international) and refer to the passcode 13688664.

This conference call will also be webcast and can be accessed from the "Investors" section of the AngioDynamics website at www.angiodynamics.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

A recording of the call will also be available from 11:00 a.m. ET on Tuesday, April 2, 2019, until 11:59 p.m. ET on Tuesday, April 9, 2019. To hear this recording, dial 1-844-512-2921 (domestic) or 1-412-317-6671 (international) and enter the passcode 13688664.

Use of Non-GAAP Measures

Management uses non-GAAP measures to establish operational goals and believes that non-GAAP measures may assist investors in analyzing the underlying trends in AngioDynamics’ business over time. Investors should consider these non-GAAP measures in addition to, not as a substitute for or as superior to, financial reporting measures prepared in accordance with GAAP. In this news release, AngioDynamics has reported adjusted EBITDAS, adjusted net income, adjusted earnings per share and free cash flow. Management uses these measures in its internal analysis and review of operational performance. Management believes that these measures provide investors with useful information in comparing AngioDynamics’ performance over different periods. By using these non-GAAP measures, management believes that investors get a better picture of the performance of AngioDynamics’ underlying business. Management encourages investors to review AngioDynamics’ financial results prepared in accordance with GAAP to understand AngioDynamics’ performance taking into account all relevant factors, including those that may only occur from time to time but have a material impact on AngioDynamics’ financial results. Please see the tables that follow for a reconciliation of non-GAAP measures to measures prepared in accordance with GAAP.

On April 2, 2019 MiNA Therapeutics, the pioneer in RNA activation (RNAa) therapeutics, reported pre-clinical data supporting the immunological effects of MTL-CEBPA and its benefits in combination with other anti-cancer interventions including sorafenib, anti-PD1 checkpoint inhibition and radiofrequency ablation (Press release, MiNA Therapeutics, APR 2, 2019, View Source [SID1234534919]). The data will be presented today in two posters at the 2019 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting taking place in Atlanta, Georgia.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"With these additional pre-clinical studies, we continue to elucidate the benefits that our lead candidate MTL-CEBPA can provide not only alone but also in combination to improve standard of care treatments," said Robert Habib, CEO of MiNA Therapeutics. "We look forward to sharing these results with the scientific community at AACR (Free AACR Whitepaper) which support our ongoing clinical investigation of MTL-CEBPA in severe liver cancer patients."

The first pre-clinical study highlights that the combination of MTL-CEBPA with sorafenib resulted in superior tumour growth inhibition and reduction of tumour biomarker alpha-fetoprotein (AFP) compared to single agents as demonstrated in an immunocompetent rat model of hepatocellular carcinoma. The anti-tumour activity of sorafenib had previously been demonstrated to be enhanced by immunological agents targeting suppressive myeloid cells in the tumour microenvironment. In the presented study, the combination of MTL-CEBPA and sorafenib was administered in a sequential regimen to "prime" tumours with MTL-CEBPA before treating with sorafenib. Most importantly, the results further support the expansion of MiNA’s Phase 1b OUTREACH trial to evaluate MTL-CEBPA in combination with sorafenib.

A second pre-clinical study describes a triple combination of MTL-CEBPA with anti-PD1 checkpoint inhibition and radiofrequency ablation in an immunocompetent mouse model of liver cancer bearing tumours on two opposite flanks. Radiofrequency ablation was performed on one flank only and treatment effects were assessed on the contralateral flank. Compared to single agent or double combinations, the triple combination demonstrated significantly improved immunological responses as well as anti-tumour activity. Immunological responses in the tumour microenvironment were evidenced by superior infiltration of cytotoxic T lymphocytes (TILs) as well as natural killer T (NKT) cells. Anti-tumour activity was evidenced by near complete inhibition of tumour growth including complete responses. Improved tumour growth inhibition in the contralateral flank suggested that the combination of MTL-CEBPA and anti-PD1 checkpoint inhibition increased the effectiveness of the abscopal effects of radiofrequency ablation.

The posters will be made available on the Company’s website in the Publications section under "RNA Activation".

Presentation information

Title: MTL-CEBPA, a drug candidate for hepatocellular-carcinoma enhances efficacy of sorafenib
Abstract No: 4455
Session: Experimental and Molecular Therapeutics – Novel Antitumor Agents 2
Date / time: Tuesday April 2, 2019 from 1:00 pm to 5:00 pm CDT

Title: MTL-CEBPA combined with radiofrequency ablation and immunotherapy enhances immunological anti-tumour response in an HCC mouse model
Abstract No: 4224
Session: Immunology – Combination Immunotherapies 2
Date / time: Tuesday April 2, 2019 from 8:00 am to 12:00 pm CDT
About MTL-CEBPA

MTL-CEBPA consists of a double stranded RNA formulated in a liposomal nanoparticle and is designed to activate the CEBPA gene. The CEBPA gene encodes CCAAT/enhancer binding protein alpha (C/EBP-α), a transcription factor that acts as a master regulator of cell lineage determination and differentiation in several tissues including myeloid cells, liver cells and adipose tissue. In cancer, C/EBP-α plays important roles in regulating both tumour growth and the tumour immune microenvironment. MTL-CEBPA is currently under evaluation in OUTREACH, a Phase Ib clinical study in patients with advanced liver cancer. The multi-centre study is assessing the safety, tolerability and anti-tumour activity of MTL-CEBPA in combination with sorafenib. To learn more about the OUTREACH clinical study, please visit our listing at clinicaltrials.gov

On April 2, 2019 PureTech Health plc (LSE: PRTC) ("PureTech Health"), an advanced biopharmaceutical company developing novel medicines for dysfunctions of the Brain-Immune-Gut (BIG) axis, reported the presentation of two scientific posters at the 2019 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting in Atlanta, Georgia (Press release, PureTech Health, APR 2, 2019, View Source [SID1234534918]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Joseph Bolen, PhD, chief scientific officer at PureTech Health, said: "PureTech Health has built a leading position in BIG therapeutic development through its affiliate technologies and is now capitalizing on this critical mass of expertise through multiple internal development programs that are delivering clinical candidates. We’re proud to present data on these programs at AACR (Free AACR Whitepaper), one of the premiere scientific meetings focused on cancer research. Galectin-9 and γδ1 T cells represent powerful immunosuppressive mechanisms across both innate and adaptive immunity. We have moved quickly to advance development of compelling candidates that could act as both monotherapies and combination therapies against cancers that currently do not respond well to approved immunotherapies. In addition to our programs targeting the body’s immune cell trafficking highway – the lymphatic system – these immuno-oncology programs round out an exciting pipeline of therapeutics targeting important regulators of the immune system."

The posters detail the Company’s development of first-in-class, fully-human monoclonal antibodies (mAbs) targeting Galectin-9 (LYT-200) and immunosuppressive γδ1 (gamma delta) T cells (LYT-210). LYT-200 and LYT-210 are unique mAbs targeting foundational, novel mechanisms of tumoral immune escape and immunosuppression in cancer, and have been tested as single agents, as well as in combination with anti-PD1 in preclinical murine and human-derived ex vivo models. As such, they represent novel additions to the armamentarium of immuno-oncology agents, with potential across multiple solid tumors including malignancies that have historically proved difficult to treat. The AACR (Free AACR Whitepaper) posters describe their development, lead candidate characterization, and pre-clinical efficacy models.

Galectin-9 is a master immunosuppressor that affects multiple cell types (e.g., regulatory and effector T cells, myeloid-derived suppressor cells, and macrophages) to induce and maintain a tumor-permissive microenvironment. As it can be both expressed by cancer cells and present in cancer tissue, and it can also be secreted into the circulation of cancer patients, targeting Galectin-9 can enable multiple anti-tumor effects. PureTech’s anti-Galectin-9 antibody, dubbed LYT-200, is being developed for difficult-to-treat malignancies, including pancreatic, cholangiocarcinoma, and certain types of colorectal and liver cancers, which remain insufficiently responsive or resistant to currently approved checkpoint inhibitors. The research presented today details the development and comprehensive characterization of LYT-200 and its efficacy in preclinical human-derived ex vivo models and a murine model. The work demonstrates efficacy to reduce tumor growth, as well as the ability of LYT-200 to reactivate human effector T cells in patient-derived tumor culture models.

Gamma Delta 1 (γδ1) T cells are an immunosuppressive subset of the γδ T cell family of immune cells, which are upregulated in multiple solid tumors including breast cancer, glioblastoma, melanoma, and pancreatic cancer. Notably, an abundance of circulating γδ1 T cells has been associated with poor response to checkpoint therapy in melanoma patients. γδ1 T cells harbor a distinct phenotype characterized by expression of the δ1 chain in the T cell receptor. Immunosuppressive γδ1 T cells function to block effector T cells, restrict anti-tumoral γδ2 T cell subset, hinder antigen-presenting dendritic cells, and attract tumor-associated macrophages and myeloid-derived suppressor cells to enhance immunosuppression in cancer. Targeting γδ1 T cells therefore has the capacity to modulate both innate and adaptive immunity, and their distinct phenotypic and functional properties make them excellent therapeutic targets in cancer. The research presented today focuses on PureTech’s leading antibody candidate aimed at depleting γδ1 T cells, showing high specificity (e.g., binding to δ1 but not the δ2 chain present on cytotoxic γδ T cells), excellent binding affinity to both human and non-human primate δ1 chains, as well as functional properties to increase T cell effector activity in human derived ex vivo models. PureTech Health believes its anti-δ1 mAb program is the only one of its kind, and the Company is now finalizing the program’s lead clinical candidate selection.

The company anticipates filing an Investigational New Drug Application (IND) for LYT-200, which targets Galectin-9, in 2020 and anticipates continuing to advance the lead clinical candidate of the γδ1 program, LYT-210, into development